Streetwise Reports – Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity Jul 20, 2022 Streetwise Reports – Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity
Proactive Investors Interview – Algernon Pharmaceuticals Study of Ifenprodil for the Treatment of IPF and Chronic Cough Reaches Key Stage Jul 18, 2022 Proactive Investors Interview – Algernon Pharmaceuticals Study of Ifenprodil for the Treatment of IPF and Chronic Cough Reaches Key Stage
Streetwise Reports – Can the Psychedelic Drug DMT Take Algernon to the Next Level? Jul 14, 2022 Streetwise Reports – Can the Psychedelic Drug DMT Take Algernon to the Next Level?
Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease Research Program with NP-251 Jul 11, 2022 Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease Research Program with NP-251
Algernon Pharmaceuticals Phase 1 DMT Stroke Study Will Start in September 2022 Jul 7, 2022 Algernon Pharmaceuticals Phase 1 DMT Stroke Study Will Start in September 2022
Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program Apr 5, 2022 Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program
Streetwise Live! – Algernon is Awaiting Approval for a Phase 1 DMT Human Stroke Study Jan 28, 2022 Streetwise Live! – Algernon is Awaiting Approval for a Phase 1 DMT Human Stroke Study
Proactive Investors Interview – Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy for DMT Intellectual Property Jan 24, 2022 Proactive Investors Interview – Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy for DMT Intellectual Property
Proactive Investors Interview – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Stroke Study Jan 19, 2022 Proactive Investors Interview – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Stroke Study
This Pharmaceutical Company Has a Brilliant Concept – An Expert Opinion Jan 17, 2022 This Pharmaceutical Company Has a Brilliant Concept – An Expert Opinion
Algernon Pharmaceuticals Ifenprodil Chronic Cough Study Receives Positive Feedback from U.S. FDA Jan 14, 2022 Algernon Pharmaceuticals Ifenprodil Chronic Cough Study Receives Positive Feedback from U.S. FDA
Streetwise Reports – Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes Jan 4, 2022 Streetwise Reports – Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes
Market One – Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment Nov 25, 2021 Market One – Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment
Proactive Investors Interview – Algernon Pharmaceuticals Receives a Positive Response from U.S. FDA on SCLC Study Nov 24, 2021 Proactive Investors Interview – Algernon Pharmaceuticals Receives a Positive Response from U.S. FDA on SCLC Study
Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 4 Nov 19, 2021 Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 4
Proactive Investors Interview – Algernon Pharmaceuticals Receives Positive Feedback On Its Planned Phase 1/2a DMT Human Stroke Stud Nov 19, 2021 Proactive Investors Interview – Algernon Pharmaceuticals Receives Positive Feedback On Its Planned Phase 1/2a DMT Human Stroke Stud
Algernon Presents Psychiatrist and Author Rick Strassman, MD on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD Nov 13, 2021 Algernon Presents Psychiatrist and Author Rick Strassman, MD on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD
Proactive Investors Interview – Algernon Pharmaceuticals Establishes Optimum Treatment Period for DMT Nov 1, 2021 Proactive Investors Interview – Algernon Pharmaceuticals Establishes Optimum Treatment Period for DMT
Powerplay by the Market Herald Interviews Christopher J. Moreau, CEO Oct 9, 2021 Powerplay by the Market Herald Interviews Christopher J. Moreau, CEO
DMT Increases Growth of Rat Neurons by 40 Percent, New Data Shows Sep 27, 2021 DMT Increases Growth of Rat Neurons by 40 Percent, New Data Shows
Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 3 Sep 23, 2021 Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 3
The Dales Report – Preclinical Study Shows Microdoses of DMT Increased Growth of Neurons Sep 13, 2021 The Dales Report – Preclinical Study Shows Microdoses of DMT Increased Growth of Neurons
Upfront with Algernon Pharmaceuticals CEO Christopher J. Moreau – Episode 2 Sep 11, 2021 Upfront with Algernon Pharmaceuticals CEO Christopher J. Moreau – Episode 2
Proactive Investors Interview – Algernon Pharmaceutical’s Preclinical Study of DMT for Stroke Confirms Growth of Neurons by 40% Sep 7, 2021 Proactive Investors Interview – Algernon Pharmaceutical’s Preclinical Study of DMT for Stroke Confirms Growth of Neurons by 40%
Psychedelic Finance – Interview with Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals Sep 7, 2021 Psychedelic Finance – Interview with Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals
Streetwise Live! – Algernon Pharmaceuticals CEO Christopher Moreau and Dr. David Nutt Discuss Phase 1 DMT Study For Stroke Jul 9, 2021 Streetwise Live! – Algernon Pharmaceuticals CEO Christopher Moreau and Dr. David Nutt Discuss Phase 1 DMT Study For Stroke
Proactive Investors Interview – Algernon Pharmaceuticals Phase 2 Human Study of Ifenprodil for IPF and Chronic Cough is Now 70% Enrolled Jul 7, 2021 Proactive Investors Interview – Algernon Pharmaceuticals Phase 2 Human Study of Ifenprodil for IPF and Chronic Cough is Now 70% Enrolled
Stockhouse – Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke Jun 22, 2021 Stockhouse – Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke
Weekend Dispensary – Could the ‘spirit molecule’ be a treatment option for stroke? May 22, 2021 Weekend Dispensary – Could the ‘spirit molecule’ be a treatment option for stroke?
Psychedelic Finance – Interview with Dr. Rick Strassman | DMT Stroke Program Consultant, Algernon Pharmaceuticals May 21, 2021 Psychedelic Finance – Interview with Dr. Rick Strassman | DMT Stroke Program Consultant, Algernon Pharmaceuticals
Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke Receives Positive FDA Feedback May 17, 2021 Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke Receives Positive FDA Feedback
PRMediaNow Algernon Pharmaceuticals Update with CEO Christopher Moreau May 13, 2021 PRMediaNow Algernon Pharmaceuticals Update with CEO Christopher Moreau
Proactive Interview regarding 50% enrollment into the IPF/Chronic Cough May 12, 2021 Proactive Interview regarding 50% enrollment into the IPF/Chronic Cough
Psychedelic Finance – Interview with Professor David Nutt | Algernon Pharmaceuticals DMT Stroke Consultant Apr 30, 2021 Psychedelic Finance – Interview with Professor David Nutt | Algernon Pharmaceuticals DMT Stroke Consultant
Interview with Algernon Pharmaceuticals CEO Christopher J. Moreau About New DMT Stroke Program Apr 13, 2021 Interview with Algernon Pharmaceuticals CEO Christopher J. Moreau About New DMT Stroke Program
